Author

admin

Browsing

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Big pharma ETFs

Many of these funds have diverse holdings across some of the most important sectors in the pharmaceutical industry, including pain therapeutics, oncology, vaccines and biotechnology. Data was gathered on August 11, 2025.

1. iShares US Pharmaceuticals ETF (ARCA:IHE)

Total assets under management: US$539.44 million

Created on May 5, 2006, this iShares ETF tracks some of the top US pharma companies. In total, the iShares US Pharmaceuticals ETF has 41 holdings, with the vast majority being large-cap stocks.

Of its holdings, Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are by far the largest portions in its portfolio, coming in at weightings of 25.51 percent and 17.68 percent, respectively. The next highest are Royalty Pharma (NASDAQ:RPRX) at 5.04 percent, Viatris (NASDAQ:VTRS) at 4.94 percent and Merck & Co (NYSE:MRK) at 4.59 percent.

2. VanEck Pharmaceutical ETF (NASDAQ:PPH)

Total assets under management: US$494.34 million

Established in late 2011, the VanEck Pharmaceutical ETF tracks the MVIS US Listed Pharmaceutical 25 Index. It has the capacity to provide big returns, even though there are some risks attached to the ETF. An analyst report indicates that investors looking for ‘tactical exposure’ to the pharma sector might consider this ETF as an investment option.

The ETF has 25 holdings, with the top five being Eli Lilly at a weight of 15.81percent, Johnson & Johnson at 12.08 percent, Novartis (NYSE:NVS) at 7.80 percent, Merck & Co. at 6.33 percent and Novo Nordisk (NYSE:NVO) at 5.94 percent.

3. Invesco Pharmaceuticals ETF (ARCA:PJP)

Total assets under management: US$240.1 million

The Invesco Pharmaceuticals ETF is primarily focused on providing exposure to US-based pharma companies. An analyst report states that this ETF chooses individual securities based on certain investment criteria, namely stock valuation and risk factors. Invesco changed the fund’s name from the Invesco Dynamic Pharmaceuticals ETF in August 2023.

This ETF was started on June 23, 2005, and currently tracks 31 companies. Its top holdings are Johnson & Johnson with a weight of 5.25 percent, Gilead Sciences (NASDAQ:GILD) at 5.08 percent, AbbVie (NYSE:ABBV) at 4.95 percent, and both Pfizer (NYSE:PFE) and Merck & Co. at 4.83 percent each.

4. SPDR S&P Pharmaceuticals ETF (ARCA:XPH)

Total assets under management: US$150.91 million

The SPDR S&P Pharmaceuticals ETF came into the market on June 19, 2006, and represents the pharmaceutical sub-industry sector of the S&P Total Markets Index. An analyst report for the ETF suggests that due to its narrow focus — which includes pharma giants that post ‘big returns’ during times of consolidation — it should not be considered for a long-term portfolio.

This pharma ETF tracks 43 holdings, with relatively close weighting among its holdings. XPH’s top five holdings are Elanco Animal Health (NYSE:ELAN) with a weight of 4.21 percent, Tarsus Pharmaceuticals (NASDAQ:TARS) with a weight of 4.18 percent, Johnson & Johnson at 4.02 percent, Royalty Pharma at 3.98 percent and Viatris at 3.89 percent.

5. KraneShares MSCI All China Health Care Index ETF

Total assets under management: US$111.67 million

The KraneShares MSCI All China Health Care Index ETF was launched in February 2018 and tracks an index of large- and mid-cap Chinese stocks in the healthcare sector, all weighted by market capitalization. According to an analyst report, the fund provides investors with ‘exposure to a relatively small slice of the Chinese economy.’

The ETF tracks 46 holdings, and its top five are BeOne Medicines at 8.26 percent, Jiangsu Hengrui Medicine (SHA:600276) at 8.24 percent, WuXi Biologics (HKEX:2269) at 6.71 percent, Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) at 5.95 percent and CSPC Pharmaceutical Group (HKEX:1093) at 5.39 percent.

Securities Disclosure: I, Meagen Seatter, hold no investment interest in any of the companies mentioned in this article.

This post appeared first on investingnews.com

Keith Weiner, founder and CEO of Monetary Metals, discusses gold and silver’s performance so far this year and shares his outlook for the rest of 2025.

He also explains what makes today’s gold bull market different than those seen in prior years.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.

After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,530.69 as of August 5, 2025, further growth could be in store in the future.

According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.04 trillion.

Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.

The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.

Data was gathered on August 5, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.

1. Tiziana Life Sciences (NASDAQ:TLSA)

Year-to-date gain: 227.8 percent
Market cap: US$256.36 million
Share price: US$2.26

Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous delivery. Tiziana’s lead candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody.

Tiziana Life Sciences shares hit US$1.69 on March 7 after the company filed its investigational new drug application to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association. However, by early April that value had fallen back to US$0.78 per share.

A series of positive news flow later in the spring helped to give Tiziana shares another boost. In April, John Hopkins University and the University of Massachusetts commenced dosing of the biotech company’s intranasal foralumab in Phase 2 trials for patients with non-active secondary progressive multiple sclerosis. On May 7, the company shared positive results from the use of its lead candidate in improving the quality of life for patients with that form of multiple sclerosis.

Tiziana is also studying the use of intranasal foralumab for treating moderate Alzheimer’s disease. On May 9, it announced that PET scans of a patient with moderate Alzheimer’s showed a significant reduction in microglia activation associated with neuroinflammation after three months of treatment.

Shares of Tiziana reached US$1.62 on May 13.

On July 21, the company announced an ‘unexpected discovery’ in its findings of an immunologic analysis of the patient with Alzheimer’s disease.

‘In an unexpected discovery, the analysis revealed an increase in phagocytosis markers in classical monocytes, suggesting that nasal foralumab may enhance their ability to clear amyloid plaques,’ the press release states. ‘This unexpected effect may open new avenues for treating Alzheimer’s Disease by targeting both inflammation and amyloid accumulation.’

Tiziana’s share price climbed through the remainder of the month, hitting a year-to-date high of US$2.50 on July 31.

2. Palvella Therapeutics (NASDAQ:PVLA)

Year-to-date gain: 224.98 percent
Market cap: US$416.08 million
Share price: US$37.64

Palvella Therapeutics is a clinical-stage biopharma developing treatments targeting rare genetic skin diseases for which there are no FDA-approved therapies. The company’s product pipeline centers on its patented QTORIN platform, which has an initial focus on rare genetic skin diseases.

Its lead product candidate, QTORIN rapamycin, is currently in a Phase 2 clinical trial in cutaneous venous malformations, and a Phase 3 clinical trial in microcystic lymphatic malformations (LM). QTORIN rapamycin has been granted breakthrough therapy designation, orphan drug designation and fast track designation from the FDA for the treatment of microcystic LMs.

After starting the year at US$12.00, shares of Palvella had surged to US$20.99 by February 18. About a week earlier, the company had shared plans to expand the Phase 3 trial to include pediatric patients from three to five years of age. That momentum in Palvella’s share price continued to rally to US$29 per share on March 13.

June produced a number of significant milestones for Palvella. On June 9, the company received initial proceedings from a grant issued by the FDA Office of Orphan Products Development for its Phase 3 trial, and on June 23, it completed enrollment for the trial with 51 subjects, 25 percent over its target. The company closed out the month with news it was added to the broad-market Russell 3000 Index and the Russell 2000 Index.

The company said it remains on track to deliver top-line Phase 3 data in Q1 2026 to support its planned new drug application submission later that year.

While the company didn’t release news in July, Palvella Therapeutics’ share price climbed significantly through the month to hit a year-to-date high of US$39.87 on July 28.

3. OKYO Pharma (NASDAQ:OKYO)

Year-to-date gain: 163.03 percent
Market cap: US$117.35 million
Share price: US$3.13

OKYO Pharma is a clinical-stage biopharma developing therapies for the treatment of neuropathic corneal pain and dry eye disease. Its lead candidate is urcosimod, a non-steroidal anti-inflammatory and non-opioid analgesic.

So far in 2025, the company has achieved multiple milestones related to its Phase 2 trial of urcosimod for treatment of neuropathic corneal pain.

On April 30, OKYO announced plans to end the trial early to analyze the data from the patients who had completed the trial, with the goal of accelerating its clinical development and expanding the program. Supporting the decision was the fact that urcosimod had previously demonstrated safety in OKYO’s completed Phase 2 trial of the candidate to treat patients with dry eye disease.

The next day, news broke that the FDA granted urcosimod fast track designation for the treatment of neuropathic corneal pain. OKYO’s stock price reached US$1.57 on May 1.

On July 17, OKYO posted strong top-line data from its Phase 2 clinical trial, and stated it is planning a meeting with the FDA to discuss next steps for its lead drug candidate. The following day, OKYO received US$1.9 million in non-dilutive funding to support its clinical development of urcosimod.

Shares of OKYO hit a year-to-date high of US$3.17 on August 5.

4. IO Biotech (NASDAQ:IOBT)

Year-to-date gain: 129.47 percent
Market cap: US$144.28 million
Share price: US$2.16

IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on its T-win technology platform, designed to activate T cells to target both tumor cells and the immune-suppressive cells. The company’s lead cancer vaccine candidate IO102-IO103, which has the brand name Cylembio, is currently in clinical trials.

The FDA granted breakthrough therapy designation to IO102-IO103 when used in combination with Merck’s (NYSE:MRK) anti-PD-1 therapy KEYTRUDA for the treatment of advanced melanoma based on positive Phase 1/2 first line metastatic melanoma data.

At the start of the year, IO Biotech completed enrollment in its Phase 2 trial of IO102-IO103 with KEYTRUDA as a treatment given before and after surgery for resectable melanoma or head and neck cancer.

On February 4, the company published results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1, which plays a key role in immune suppression.

In mid-March, IO Biotech was named to Fast Company’s list of the World’s Most Innovative Companies of 2025. The following month, the company presented new preclinical data for its lead candidate IO102-IO103 as well as IO170, which targets Transforming Growth Factor beta.

In its Q1 2025 financial results and business highlights released on May 14, IO Biotech shared that a readout of primary endpoint data from its pivotal Phase 3 trial of its lead investigational therapeutic cancer vaccine in patients with advanced melanoma is expected in the third quarter of 2025.

Shares of IO Biotech reached a year-to-date high of US$2.40 on July 28.

5. Spero Therapeutics (NASDAQ:SPRO)

Year-to-date gain: 110.95 percent
Market cap: US$124.12 million
Share price: US$2.22

Spero Therapeutics is developing novel treatments for rare diseases and multi-drug resistant bacterial infections with high unmet need. The company’s lead drug candidate is tebipenem pivoxil hydrobromide (HBr), a late-stage development asset developed in collaboration with pharma giant GSK (NYSE:GSK) to treat complicated urinary tract infections (cUTIs), including pyelonephritis.

Spero has an exclusive license agreement with GSK for the development and commercialization of the drug candidate in all ex-Asia markets. The FDA has granted tebipenem HBr qualified infectious disease product and fast track designations.

Shares in Spero traded below US$1.00 for much of the first half of 2025. However, the stock’s value surged 245 percent on May 28 to reach US$2.35 per share after Spero reported that its Phase 3 trial evaluating tebipenem HBr for treating cUTIs met its primary endpoint and stopped early for efficacy. GSK plans to include the findings in a filing to the FDA during H2.

Spero shares reached a year-to-date high of US$3.04 on July 9.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

(TheNewswire)

TORONTO, ON, August 13, 2025 TheNewswire – Silver Crown Royalties Inc. ( Cboe: SCRI,OTC:SLCRF; OTCQX: SLCRF; FRA: QS0) ( ‘Silver Crown’ or the ‘Company’ ) is pleased to announce that, further to its press release dated August 7, 2025, it has closed the acquisition of a royalty on 90% of the cash equivalent of silver produced each quarter from the past producing Scotia Mine (the ‘Silver Royalty’ ) with EDM Resources Inc. ( TSX-V: EDM; FSE: P3Z) ( ‘EDM’ ). The Silver Royalty provides for minimum of the cash equivalent of 7,000 ounces per year for 10 years starting at commercial production on the Scotia Mine. SCRi paid $250,000 in cash at closing and issued 60,000 units (‘ Units ‘) to EDM per Unit at a deemed value of C$10.00, with each Unit consisting of a common share in the capital of SCRi (‘ Common Share ‘) and one warrant exercisable into an additional Common Share at a price of C$13.00 for a period of 36 months following the date hereof. SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty.

ABOUT EDM RESOURCES INC.

EDM Resources Inc. (‘EDM’) ( TSX-V: EDM; FSE: P3Z) is a Canadian exploration and mining company that has full ownership of the Scotia Mine and related facilities near Halifax, Nova Scotia. Through its wholly owned subsidiary, EDM also holds several prospective exploration licenses near its Scotia Mine and in the surrounding regions of Nova Scotia .

ABOUT Silver Crown Royalties INC.

Founded by seasoned industry professionals, Silver Crown Royalties ( Cboe: SCRI | OTCQX: SLCRF | FRA: QS0) is a publicly traded silver royalty company dedicated to generating free cash flow. Silver Crown (SCRi) currently holds five silver royalties. Its business model offers investors exposure to precious metals, providing a natural hedge against currency devaluation while mitigating the adverse effects of production-related cost inflation. SCRi strives to minimize the economic burden on mining projects while simultaneously maximizing shareholder returns. For further information, please contact:

Silver Crown Royalties Inc.

Peter Bures, Chairman and CEO

Telephone: (416) 481-1744

Email: pbures@silvercrownroyalties.com

FORWARD-LOOKING STATEMENTS

This release contains certain ‘forward looking statements’ and certain ‘forward-looking information’ as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as ‘may’, ‘will’, ‘should’, ‘expect’, ‘intend’, ‘estimate’, ‘anticipate’, ‘believe’, ‘continue’, ‘plans’ or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements and information include, but are not limited to, SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty . Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual actions, events or results to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the impact of general business and economic conditions; the absence of control over mining operations from which SCRi will purchase gold and other metals or from which it will receive royalty payments and risks related to those mining operations, including risks related to international operations, government and environmental regulation, delays in mine construction and operations, actual results of mining and current exploration activities, conclusions of economic evaluations and changes in project parameters as plans continue to be refined; accidents, equipment breakdowns, title matters, labor disputes or other unanticipated difficulties or interruptions in operations; SCRi’s ability to enter into definitive agreements and close proposed royalty transactions; the inherent uncertainties related to the valuations ascribed by SCRi to its royalty interests; problems inherent to the marketability of gold and other metals; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; industry conditions, including fluctuations in the price of the primary commodities mined at such operations, fluctuations in foreign exchange rates and fluctuations in interest rates; government entities interpreting existing tax legislation or enacting new tax legislation in a way which adversely affects SCRi; stock market volatility; regulatory restrictions; liability, competition, the potential impact of epidemics, pandemics or other public health crises on SCRi’s business, operations and financial condition, loss of key employees. SCRi has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. SCRi undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available.

This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities of the Company in Canada, the United States or any other jurisdiction. Any such offer to sell or solicitation of an offer to buy the securities described herein will be made only pursuant to subscription documentation between the Company and prospective purchasers. Any such offering will be made in reliance upon exemptions from the prospectus and registration requirements under applicable securities laws, pursuant to a subscription agreement to be entered into by the Company and prospective investors. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

CBOE CANADA DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Copyright (c) 2025 TheNewswire – All rights reserved.

News Provided by TheNewsWire via QuoteMedia

This post appeared first on investingnews.com

Elon Musk on Monday threatened Apple with legal action over alleged antitrust violations related to rankings of the Grok AI chatbot app, which is owned by his artificial intelligence startup xAI.

“Apple is behaving in a manner that makes it impossible for any AI company besides OpenAI to reach #1 in the App Store, which is an unequivocal antitrust violation. xAI will take immediate legal action,” Musk wrote in a post on his social media platform X.

Apple declined to comment on Musk’s threat.

“Why do you refuse to put either X or Grok in your ‘Must Have’ section when X is the #1 news app in the world and Grok is #5 among all apps? Are you playing politics?” Musk said in another post.

Apple last year partnered with OpenAI to integrate its ChatGPT chatbot into iPhone, iPad, Mac laptop and desktop products. Musk at the time said: “If Apple integrates OpenAI at the OS level, then Apple devices will be banned at my companies. That is an unacceptable security violation.”

Prior to his legal threats against Apple, Musk had celebrated Grok surpassing Google as the fifth top free app on the App Store. When contacted by CNBC, xAI did not immediately respond to a request for further information on a potential lawsuit.

CNBC confirmed that ChatGPT was ranked No. 1 in the top free apps section of the American iOS store, and was the only AI chatbot in Apple’s “Must-Have Apps” section. The App Store also featured a link to download OpenAI’s new flagship AI model, ChatGPT-5 at the top of its “Apps” section.

OpenAI on Thursday announced GPT-5, its latest and most advanced large-scale AI model, following xAI’s release of its newest chatbot, Grok 4, last month.

Musk has an ongoing feud with ChatGPT maker OpenAI, which he co-founded in 2015. The billionaire stepped down from its board in 2018, four years after saying that AI was “potentially more dangerous than nukes.”

He is now suing the Microsoft-backed startup, and its CEO Sam Altman, alleging they abandoned OpenAI’s founding mission to develop artificial intelligence “for the benefit of humanity broadly.”

Robert Keele, who headed the legal department at xAI, announced last week that he had left the company to spend more time with his family. In his announcement, Keele also acknowledged “daylight between our worldviews,” referring to Musk.

In response to Musk’s antitrust threats against Apple, OpenAI CEO Sam Altman said in an X post: “This is a remarkable claim given what I have heard alleged that Elon does to manipulate X to benefit himself and his own companies and harm his competitors and people he doesn’t like.”

This is not the first time Apple has been challenged on antitrust grounds. In a landmark case, the Department of Justice last year sued the company over charges of running an iPhone ecosystem monopoly.

In June, a panel of judges also denied an emergency application from Apple to halt the changes to its App Store resulting from a ruling that the company could no longer charge a commission on payment links inside its apps, nor tell developers how the links should look.

— CNBC’s Kif Leswing and Lora Kolodny contributed to this article.

This post appeared first on NBC NEWS

House GOP fiscal hawks have requested tens of millions of federal dollars for projects in their home districts for fiscal year 2026, an analysis by Fox News Digital has found.

It’s common practice for congressional lawmakers to request funding for specific community initiatives for the people they represent – measures called ‘earmarks.’ Critics of such funding have often referred to it as ‘pork,’ however.

This coming fiscal year, beginning on Oct. 1, is no different – both Republicans and Democrats have requests totaling over a billion dollars in earmarks so far. 

That includes conservatives in the House of Representatives who have been known to criticize what they describe as excessive or bloated government spending.

House Freedom Caucus Chair Andy Harris, R-Md., for instance, has been approved for more than $55 million in federal funding for projects in his district. 

The figure includes $9 million for the Middle River Fire Company to make improvements and upgrades to its facilities, and $1 million for the development of a Doctor of Veterinary Medicine program at the University of Maryland Eastern Shore. 

The majority of Harris’ requests are aimed at rural development in his district and the Army Corps of Engineers. Three earmarks were requested for clean water initiatives.

Harris told Fox News Digital when reached for comment on the funds, ‘These awards are certified to directly benefit taxpayers in the district—drawing from existing grant programs that are funded annually. It’s far better for elected members of Congress to designate where that money goes than to leave those decisions to unelected federal bureaucrats. There are no additional funds appropriated for Community Project Funding – they all fall within the agency’s appropriation.’

Rep. Tim Burchett, R-Tenn., a self-described deficit hawk, was approved for just over $10 million so far. That includes over $4 million for Flexible Neutron Source, a research tool at the University of Tennessee, and $2 million for veterans housing in Knox County.

House Freedom Caucus member Rep. Clay Higgins, R-La., was approved for more than $18 million in earmarks – with the largest request being $4,200,000 for the Silicon Bayou Semiconductor Technology Center at the University of Louisiana, Lafayette.

Higgins’ total sum also includes funding for Army Corps of Engineers projects, as well as rural hospital, law enforcement and clean water initiatives.

He also submitted a joint request with House Majority Leader Steve Scalise, R-La., for $131,500,000 toward a levee and floodgate system, called the Morganza to the Gulf of Mexico Project, aimed at storm damage prevention.

Rep. Lauren Boebert, R-Colo., another member of the House Freedom Caucus, got nearly $15 million in community funding projects approved, chiefly aimed at clean water programs and highway infrastructure.

Boebert was vehemently against earmarks when she first came to Congress. Her opinion has changed since then, however, due to Republican-led changes to the process – which she explained in a 2023 op-ed in the Aspen Times.

She made a similar argument to Fox News Digital when reached for this story: ‘I fought for real reforms to the appropriations process in 2023 to make sure my constituents’ tax dollars go to necessary infrastructure projects, not the wasteful and corrupt spending schemes that took place under Nancy Pelosi.’

‘My district’s roads are crumbling, and our water keeps getting sent to California, where it’s wasted, because Colorado’s politicians won’t invest in water storage or infrastructure investments. My constituents pay federal taxes just like everyone else, and they should see their dollars benefit their communities instead of being sent to sanctuary cities like Denver,’ Boebert said.

Conservative libertarian Rep. Thomas Massie, R-Ky., also got some community funding, though only totaling $5 million approved so far. Massie’s requests so far are all focused on construction and rehabilitation for Cincinnati/Northern Kentucky International Airport.

Massie told Fox News Digital of the funding, ‘I serve on the Transportation and Infrastructure Committee because I believe the federal government has a legitimate role in transportation infrastructure, and the legislature has the constitutional authority to direct the funding of those projects.’

‘In fact, I have voted in the GOP conference more than once to restore congressionally directed spending in the context of transportation infrastructure,’ Massie said.

And Rep. Marjorie Taylor Greene, R-Ga., chair of the subcommittee for Delivering on Government Efficiency (DOGE), got nearly $10 million in earmarks approved for her rural-suburban Georgia district. 

Those funding requests are largely comprised of infrastructure initiatives, clean water programs, and law enforcement-related projects for Floyd County and other areas.

While known as a fiscal hawk, it’s worth noting that the majority of Greene’s criticism of government spending is directed at foreign aid.

Greene said she was glad to be able to provide for her district when reached for comment by Fox News Digital.

‘I’m proud to bring federal tax dollars back home to Northwest Georgia – where they belong. My constituents work hard, and for far too long, Washington has sent their money to fund foreign wars, foreign governments and globalist pet projects. When I first got to Congress, I opposed the earmark process because I believed it was a tool of the Swamp. But after seeing how it works today, I’ve realized that if we don’t fight to bring money back to our districts, the money goes elsewhere,’ Greene said.

‘I’ll never support billions for Ukraine or other endless wars, but I will absolutely fight to secure critical investments in Northwest Georgia, from water systems and sewer expansions to public safety equipment, roads and broadband.’

The aforementioned lawmakers’ spending requests are far from an exhaustive total list across the entire House, but fiscal conservatives’ earmark proposals show just how widespread the practice is within Congress – on both sides of the aisle.

Republicans have made some changes to the process as of FY2025, however, to narrow what’s allowed.

In an effort to block out funding requests for ‘woke’ or socially progressive policies, GOP appropriators have barred earmarks for most nonprofit organizations.

That move likely saved hundreds of millions of dollars in annual spending, but Democrats decried it as a block on federal funding for LGBT initiatives.

Fox News Digital reached out to spokespeople for Burchett and Higgins for comment but did not receive a response.

This post appeared first on FOX NEWS

President Donald Trump’s week will culminate in a high-stakes summit with Russian President Vladimir Putin in Alaska, where the two leaders are expected to discuss the war in Ukraine and the broader state of U.S.–Russia relations on the global stage.

The summit, scheduled for Friday, has drawn international scrutiny amid concerns that Washington and Moscow could attempt to broker terms for ending the conflict without formally involving Ukrainian President Volodymyr Zelenskyy, leaving him only a tacit role in negotiations.

Trump has previously said that Putin and Zelenskyy were close to a ceasefire deal but signaled that war-weary Kyiv would have to concede significant territory, an outcome that Ukrainians and many European allies oppose.

Russian forces currently occupy approximately one-fifth of Ukraine’s territory stretching from the Russian border to Crimea — including regions vital to the country’s economy, rich in minerals, industry, and home to Europe’s largest nuclear power plant.

Both the White House and the Kremlin have acknowledged Zelenskyy’s request to join the talks, though no formal invitation has been extended to the Ukrainian leader. If granted a seat at the table, it would mark the first face-to-face meeting between Zelenskyy and Putin since the Kremlin launched its full-scale invasion of Ukraine in February of 2022.

The summit comes as Russia’s war grinds into its third year and fifth month, with Moscow showing little sign of abandoning its efforts to erode Ukraine’s sovereignty and reassert the territorial influence of the former Soviet empire.

The Kremlin said in a statement on Saturday that Trump and Putin are expected to ‘focus on discussing options for achieving a long-term peaceful resolution’ in Ukraine. ‘This will evidently be a challenging process, but we will engage in it actively and energetically,’ the statement added.

‘The US has the power to force Russia to negotiate seriously’

Over the weekend, several European leaders voiced support for Zelenskyy’s push to attend this week’s summit, amid growing concerns that Kyiv’s long-term security could be negotiated without its direct involvement.

The leaders of Britain, France, Germany, Italy, Poland, Finland and the European Commission said in a joint statement that any diplomatic solution brokered between Trump and Putin must uphold the security interests of both Ukraine and Europe.

‘The U.S. has the power to force Russia to negotiate seriously,’ European Union foreign policy chief Kaja Kallas told Reuters on Sunday. ‘Any deal between the U.S. and Russia must have Ukraine and the EU included, for it is a matter of Ukraine’s and the whole of Europe’s security,’ she added.

NATO Secretary General Mark Rutte also voiced support for Zelenskyy’s attendance at the meeting and called the summit an opportunity to measure how serious Putin is about ‘bringing this terrible war to an end.’ 

Zelenskyy thanked European leaders for their support and said that ‘the end of the war must be fair.’

‘I am grateful to everyone who stands with Ukraine and our people today for the sake of peace in Ukraine, which is defending the vital security interests of our European nations,’ he said.

This post appeared first on FOX NEWS

President Donald Trump is weighing whether to deploy up to 1,000 National Guard troops to Washington, D.C., as early as this week, Fox News has learned, in an effort to help deal with what he characterized as a surge in violent crime. 

The plans come just one day after Trump vowed on Truth Social to evict homeless persons from that nation’s capital. ‘The Homeless have to move out, IMMEDIATELY,’ Trump said on social media. ‘We will give you places to stay, but FAR from the Capital. The Criminals, you don’t have to move out. We’re going to put you in jail where you belong.’

Trump’s plans, which are expected to be detailed further at a 10 a.m. press conference Monday, would likely involve members of the D.C. National Guard, or the 2,700-member National Guard force that acts at the express authority of the commander in chief.

Unlike other branches, Trump would not have to get the sign off of local authorities to act — likely making their activation a tempting option.

When speaking to reporters in the Oval Office last week, Trump railed against what he described as a ‘ridiculous’ level of crime in the nation’s capital, buffeted most recently by the assault on a former DOGE staffer earlier this month.

‘We want to have a great, safe capital,’ Trump said last week. ‘And we’re going to have it.’

Trump also told reporters that his White House lawyers are looking into ending the Home Rule Act, a law passed by Congress in 1973 that gave Washington, D.C., residents the right to elect their own mayor and local representatives. 

White House press secretary Karoline Leavitt also told reporters last week that Trump had ordered law enforcement personnel to increase their presence in the capital, though the additional details on the scope and timeframe of that presence remain unclear. 

Trump is expected to address those plans in a press conference Monday morning. 

However, for Trump, delivering on this promise could be fraught with long-term legal complications — in part, because crime in the city is actually down to its lowest point in nearly 30 years.

Violent crime in the first seven months of 2025 has dropped by roughly 26% compared to 2024, according to data compiled by the D.C. Police Department and released earlier this month. Overall, crime in the nation’s capital has dropped by roughly 7%.

On Sunday, White House deputy chief of staff Stephen Miller said in an interview with NewsNation that Washington, D.C., ‘is more violent than Baghdad.’ 

Washington, D.C., Mayor Muriel Bowser, for her part, told MSNBC in an interview Sunday that ‘Any comparison to a war-torn country is hyperbolic and false.’

However, it’s not the first time Trump has sought to crack down on crime in the nation’s capital — an effort he has returned to frequently, including during his first term in office.

Trump in March signed an executive order, ‘Making DC Safe and Beautiful Task Force,’ designed to address issues with a city he has long derided as ‘filthy,’ ‘horribly run’ and ‘crime-ridden,’ among other things. ‘We want to have a great, safe capital,’ he told reporters. ‘And we’re going to have it. And that includes cleanliness and it includes other things.’

However, those powers aren’t indefinite, experts explained to Fox News Digital.

Trump does have the authority to activate the 2,700-member D.C. National Guard without the approval of local officials. Guard troops provide ‘mission-ready personnel and units for active duty in the armed services’ in Washington, D.C., according to their website.

Beyond that, Trump’s ability to exercise authority in the nation’s capital is bound by the Home Rule Act. 

In the more than 50 years since that law was passed, ‘there really hasn’t been a serious conversation about ending home rule governance,’ George Derek Musgrove, a history professor at the University of Maryland in Baltimore County, told Fox News in an interview.

‘And the problem with our federal system is that there are places where Trump really doesn’t have any supporters, and therefore, with the limits of executive power, really doesn’t have that much sway,’ Musgrove said. ‘And he’s constantly probing for ways around that.’

Other options available to Trump aren’t without their own limits. In order to call up the local police force for any meaningful length of time, as Trump has suggested, a president must be able to assert ‘special conditions of an emergency nature,’ according to the 1970s law.

‘If D.C. doesn’t get its act together, and quickly, we will have no choice but to take federal control,’ Trump said last week. 

However, that’s easier said than done, individuals familiar with the law told Fox News Digital.

‘DC is just a tempting target because there’s not even a lot of legal gymnastics you have to do in order to exert tremendous power [in a city with ]a 90% Democratic jurisdiction. He has it already,’ Musgrove said.

‘But it is morally questionable, I think, and violates democratic principles,’ he added.

This post appeared first on FOX NEWS